Zurcher Kantonalbank Zurich Cantonalbank Buys 17,822 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 585,686 shares of the company’s stock after purchasing an additional 17,822 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Teva Pharmaceutical Industries were worth $18,279,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in TEVA. Wellington Management Group LLP boosted its holdings in Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after acquiring an additional 6,878,304 shares in the last quarter. Farallon Capital Management LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter valued at $100,939,000. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. Polar Capital Holdings Plc bought a new stake in Teva Pharmaceutical Industries in the third quarter valued at $80,983,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 13.6% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock valued at $658,161,000 after acquiring an additional 3,896,790 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total value of $1,871,754.28. Following the completion of the transaction, the insider owned 224,940 shares of the company’s stock, valued at $6,779,691.60. The trade was a 21.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Placid Jover sold 14,150 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $448,130.50. Following the completion of the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at approximately $214,532.58. This represents a 67.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 920,901 shares of company stock worth $30,056,789 over the last quarter. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $31.23 on Thursday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The firm has a market capitalization of $35.90 billion, a P/E ratio of 26.02, a P/E/G ratio of 2.74 and a beta of 0.76. The business has a fifty day simple moving average of $31.35 and a two-hundred day simple moving average of $28.87. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.16 and a 12 month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Piper Sandler reissued an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Scotiabank raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Truist Financial raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Barclays raised their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Finally, Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $38.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.